Tisdale Risk Score for QT Prolongation
Risk of QTc prolongation: –
Interpretation: –
The Tisdale Risk Score is a clinically validated tool used to predict the risk of drug-induced corrected QT (QTc) interval prolongation in hospitalized patients. Specifically, it assesses the probability of the QTc interval exceeding 500 msec or increasing by more than 60 msec from baseline, both of which are critical thresholds for the development of Torsades de Pointes (TdP), a life-threatening ventricular arrhythmia.
Developed by Dr. James Tisdale and colleagues, the score is particularly useful in Cardiac Care Units (CCU) and Intensive Care Units (ICU), where patients are often exposed to multiple QTc-prolonging medications and metabolic stressors.
1. Scoring Components
The Tisdale Risk Score assigns points based on ten clinical and laboratory variables. The total possible score is 21.
| Risk Factor | Points |
| Age $\ge$ 68 years | 1 |
| Female Gender | 1 |
| Use of Loop Diuretics (e.g., Furosemide) | 1 |
| Serum Potassium $\le$ 3.5 mEq/L | 2 |
| Admission QTc $\ge$ 450 msec | 2 |
| Acute Myocardial Infarction | 2 |
| Sepsis | 3 |
| Heart Failure | 3 |
| One QTc-prolonging drug | 3 |
| Two or more QTc-prolonging drugs | 3 additional (6 total) |
2. Risk Stratification and Interpretation
The total score categorizes patients into three risk levels, providing a framework for clinical monitoring and intervention.
| Total Score | Risk Level | Incidence of QTc > 500ms |
| $\le$ 6 points | Low Risk | ~15% |
| 7 – 10 points | Moderate Risk | ~37% |
| $\ge$ 11 points | High Risk | ~73% |
Clinical Performance
- Sensitivity: Approximately 74% for predicting significant QTc prolongation in cardiac units.
- Specificity: Approximately 77%.
- Negative Predictive Value (NPV): High (up to 97% in some ICU cohorts), meaning a low score is a very reliable indicator that the patient is unlikely to develop severe QTc prolongation.
3. Clinical Application and Management
The score is designed to be used at the point of care, especially when a clinician is considering starting a new medication known to prolong the QT interval (e.g., Amiodarone, Azithromycin, or Haloperidol).
Recommended Actions for High-Risk Patients ($\ge$ 11):
- Alternative Therapy: Search for non-QT-prolonging alternatives to the intended drug.
- Electrolyte Optimization: Maintain Potassium ($K^+$) $> 4.0$ mEq/L and Magnesium ($Mg^{2+}$) $> 2.0$ mg/dL.
- Increased Monitoring: Obtain a baseline ECG and repeat ECGs 8–12 hours after starting the drug, then daily until a steady state is reached.
- Pharmacist Consultation: Review the medication profile for potential pharmacokinetic drug-drug interactions that could further increase blood levels of QTc-prolonging agents.
4. References and Links
Primary Reference
- Tisdale JE, et al. (2013). Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. Circulation: Cardiovascular Quality and Outcomes. Read on PubMed/AHA
Clinical Decision Support
- MDCalc: Tisdale Risk Score for QT Prolongation Calculator
- CredibleMeds: The gold-standard database for identifying QTc-prolonging drugs. CredibleMeds.org
- Frontiers in Cardiovascular Medicine (2026 Update): Tisdale-score-based risk stratification in patients receiving azole antifungals. Full Article
